WASHINGTON — Nine drugmakers on Friday are set to unveil deals with the Trump administration to lower the prices of some of their drugs, marking the administration’s largest such deal to date. The deals are the latest in a series of agreements with drugmakers that are aimed at lowering prices to levels paid by peer…
For BioMarin CEO Alexander Hardy, this morning’s purchase of Amicus Therapeutics for $4.8 billion represents a long-awaited major bet — and one Wall Street has been waiting for. Hardy, previously CEO of Roche’s Genentech unit, took over for longtime BioMarin CEO Jean Jacques Biename. Since his appointment was announced, BioMarin shares have fallen by more…
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which…
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but already we expect to catch up on our reading list, promenade with the official mascots, and escort Mrs….
WASHINGTON — A new program intended to fast-track drug reviews at the Food and Drug Administration is quickly becoming a way for the White House and top political officials at the agency to exert control over which medicines make their way fastest to patients in the United States. The FDA has historically aimed to keep…
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about the company’s future R&D prospects. Given its large R&D budget, it was natural to use Pfizer as a barometer of the pharmaceutical industry, which was in the midst of a productivity slump. In the 1990s, the Food…
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are enveloping the Pharmalot campus, where the official mascots are foraging for noshes and keeping strangers at bay. As for us, we are engaged in the usual rituals, starting with firing up the coffee kettle — our…
Eli Lilly’s investigational obesity pill largely helped patients maintain their weight loss after they switched from the potent injectable treatments Wegovy and Zepbound, the company said Thursday, results that could widen the appeal of the pill. In a Phase 3 trial, one cohort of patients had an average starting weight of 113.5 kg. After over…
When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy next year, it pointed them to an alternative way to get the treatments: Buy them themselves. In a notice viewed by STAT, HCA said use of the GLP-1 weight loss…
More than three dozen state attorneys general are urging Meta to better enforce its policies to thwart a “surge of misleading” pharmaceutical and wellness ads for weight loss drugs on Instagram and Facebook. And the state officials also want the company to take additional measures to prevent AI-generated content in the ads. In a letter…